Bio‑Techne expanded its collaboration with Oxford Nanopore Technologies to develop and commercialize a broader portfolio of targeted enrichment sequencing kits for screening and diagnosing heritable genetic disorders. The agreement extends their partnership through 2032 and grants Bio‑Techne commercial rights to build beyond the initial carrier-screening product launched earlier this year. Company executives said the move aims to accelerate clinical adoption of long‑read nanopore assays for genetic disease testing and maintain first‑mover advantage in targeted long‑read diagnostics.